BioAtla Inc

NAS:BCAB (USA)   Ordinary Shares
$ 2.25 -0.1 (-4.26%) 04:00 PM EST
At Loss
P/B:
1.53
Market Cap:
$ 108.22M
Enterprise V:
$ 4.02M
Volume:
398.98K
Avg Vol (2M):
575.32K
Volume:
398.98K
At Loss
Avg Vol (2M):
575.32K

Business Description

BioAtla Inc
NAICS : 541714 SIC : 2833
ISIN : US09077B1044

Share Class Description:

BCAB: Ordinary Shares
Description
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Name Current Vs Industry Vs History
Cash-To-Debt 45.31
Equity-to-Asset 0.59
Debt-to-Equity 0.04
Debt-to-EBITDA -0.02
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 35.76
9-Day RSI 35.24
14-Day RSI 39.26
6-1 Month Momentum % 79.85
12-1 Month Momentum % -30.35

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.11
Quick Ratio 4.11
Cash Ratio 3.93

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -12.6
Shareholder Yield % 1.31

Profitability Rank

Name Current Vs Industry Vs History
ROE % -98.51
ROA % -70.07
ROIC % -1511.26
ROC (Joel Greenblatt) % -3117.03
ROCE % -88.35